THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION

Randomized clinical trials results have shown the advantage of non-selective EGFR tyrosine kinase inhibitor 2nd generation – afatinib compared with platinum-based chemotherapy in adenocarcinoma EGFR-positive patients in both the first and second-line of treatment. Shown significant improvement in PFS compared with standard platinum contain regimen and gefitinib in the first line of treatment. Also afatinib demonstrated the efficacy in the second line of treatment of squamous cell carcinoma of lung. The advantage of OS demonstrated in the subgroup of patients with Del19 in the global randomized clinical trials. According to the local experience FSBSI «Russian Cancer Research Center n.a. N.N.Blokhin» ORR afatinib therapy was 62.7% in the tumor growth control 94.1%. Median PFS – 18.0 months. The most common adverse events observed a rash, paronychia, and diarrhea requiring dose reduction of up to 30 and 20 mg / day, 34.5% and 16.4% of patients, espectively. On the whole, marked by a favorable toxicity profile and improve the quality of patients life.